Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.

Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno P, Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS.

Eur Urol. 2019 Oct;76(4):469-478. doi: 10.1016/j.eururo.2019.06.030. Epub 2019 Jul 22.

2.

Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer.

Sharp A, Porta N, Lambros MBK, Welti JC, Paschalis A, Raj GV, Plymate SP, de Bono JS.

J Clin Oncol. 2019 Aug 20;37(24):2182-2184. doi: 10.1200/JCO.19.01104. Epub 2019 Jul 2. No abstract available.

PMID:
31265359
3.

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.

Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, Aversa C, Figueiredo I, Fraser J, Ahmad Z, Lu C, Rescigno P, Kolinsky M, Bertan C, Seed G, Riisnaes R, Miranda S, Crespo M, Pereira R, Ferreira A, Fowler G, Ebbs B, Flohr P, Neeb A, Bianchini D, Petremolo A, Sumanasuriya S, Paschalis A, Mateo J, Tunariu N, Yuan W, Carreira S, Plymate SR, Luo J, de Bono JS.

Eur Urol. 2019 Nov;76(5):676-685. doi: 10.1016/j.eururo.2019.04.006. Epub 2019 Apr 27.

4.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

5.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

6.

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.

Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, Chandler R, Mehra N, Fowler G, Ebbs B, Flohr P, Miranda S, Yuan W, Mackay A, Ferreira A, Pereira R, Bertan C, Figueiredo I, Riisnaes R, Rodrigues DN, Sharp A, Goodall J, Boysen G, Carreira S, Bianchini D, Rescigno P, Zafeiriou Z, Hunt J, Moloney D, Hamilton L, Neves RP, Swennenhuis J, Andree K, Stoecklein NH, Terstappen LWMM, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5635-5644. doi: 10.1158/1078-0432.CCR-18-0862. Epub 2018 Aug 9.

PMID:
30093450
7.

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.

Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D.

Nature. 2018 Jul;559(7713):285-289. doi: 10.1038/s41586-018-0291-z. Epub 2018 Jul 4.

8.

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucianò R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A.

Nature. 2018 Jul;559(7714):363-369. doi: 10.1038/s41586-018-0266-0. Epub 2018 Jun 27.

9.

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.

Chong IY, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R, Pettitt S, Wilkerson P, Lambros MB, Reis-Filho JS, Ramessur A, Davidson M, Chau I, Cunningham D, Ashworth A, Lord CJ.

Gut. 2018 Oct;67(10):1780-1792. doi: 10.1136/gutjnl-2017-314408. Epub 2017 Aug 22.

10.

Application of Liquid Biopsies in Cancer Targeted Therapy.

Sumanasuriya S, Lambros MB, de Bono JS.

Clin Pharmacol Ther. 2017 Nov;102(5):745-747. doi: 10.1002/cpt.764. Epub 2017 Jul 29. Review.

11.

Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.

Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS.

Oncotarget. 2017 Jan 24;8(4):6057-6066. doi: 10.18632/oncotarget.14011.

12.

Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.

Colombo PE, du Manoir S, Orsett B, Bras-Gonçalves R, Lambros MB, MacKay A, Nguyen TT, Boissière F, Pourquier D, Bibeau F, Reis-Filho JS, Theillet C.

Oncotarget. 2015 Sep 29;6(29):28327-40. doi: 10.18632/oncotarget.5069.

13.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A'hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, Hardisson D, Lord CJ, Kumar-Sinha C, Ashworth A, Weigelt B, Sapino A, Chinnaiyan AM, Maher CA, Reis-Filho JS.

J Pathol. 2014 Apr;232(5):553-65. doi: 10.1002/path.4325. Epub 2014 Feb 5.

14.

Genomic profiling of histological special types of breast cancer.

Horlings HM, Weigelt B, Anderson EM, Lambros MB, Mackay A, Natrajan R, Ng CK, Geyer FC, van de Vijver MJ, Reis-Filho JS.

Breast Cancer Res Treat. 2013 Nov;142(2):257-69. doi: 10.1007/s10549-013-2740-6. Epub 2013 Oct 27.

PMID:
24162157
15.

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.

Clin Cancer Res. 2013 Jul 1;19(13):3533-44. doi: 10.1158/1078-0432.CCR-12-3815. Epub 2013 May 14.

16.

Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations.

Wetterskog D, Wilkerson PM, Rodrigues DN, Lambros MB, Fritchie K, Andersson MK, Natrajan R, Gauthier A, Di Palma S, Shousha S, Gatalica Z, Töpfer C, Vukovic V, A'Hern R, Weigelt B, Vincent-Salomon A, Stenman G, Rubin BP, Reis-Filho JS.

Histopathology. 2013 Mar;62(4):543-50. doi: 10.1111/his.12050. Epub 2013 Feb 12.

17.

Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas.

Kurelac I, MacKay A, Lambros MB, Di Cesare E, Cenacchi G, Ceccarelli C, Morra I, Melcarne A, Morandi L, Calabrese FM, Attimonelli M, Tallini G, Reis-Filho JS, Gasparre G.

Hum Mol Genet. 2013 Jan 15;22(2):226-38. doi: 10.1093/hmg/dds422. Epub 2012 Oct 9.

PMID:
23049073
18.

Genomic characterisation of acral melanoma cell lines.

Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R.

Pigment Cell Melanoma Res. 2012 Jul;25(4):488-92. doi: 10.1111/j.1755-148X.2012.01016.x.

PMID:
22578220
19.

Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis.

Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Marchiò C, Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JS.

Histopathology. 2012 May;60(6B):E115-30. doi: 10.1111/j.1365-2559.2012.04207.x. Epub 2012 Apr 4.

20.

Functional characterization of the 19q12 amplicon in grade III breast cancers.

Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS.

Breast Cancer Res. 2012 Mar 20;14(2):R53.

21.

A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'Hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turaljic S, Furney SJ, Marais R, Rodruigues DN, Flora AC, Wai P, Pawar V, McDade S, Carroll J, Stoppa-Lyonnet D, Green AR, Ellis IO, Swanton C, van Diest P, Delattre O, Lord CJ, Foulkes WD, Vincent-Salomon A, Ashworth A, Stern MH, Reis-Filho JS.

J Pathol. 2012 May;227(1):29-41. doi: 10.1002/path.4003. Epub 2012 Feb 23.

22.

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'Hern R, Marchiò C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS.

J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.

23.

Whole genome sequencing of matched primary and metastatic acral melanomas.

Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, Mackay A, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Thomas M, Stamp G, Larkin J, Reis-Filho JS, Marais R.

Genome Res. 2012 Feb;22(2):196-207. doi: 10.1101/gr.125591.111. Epub 2011 Dec 19.

24.

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.

Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, Chinnaiyan AM.

Nat Med. 2011 Nov 20;17(12):1646-51. doi: 10.1038/nm.2580.

25.

Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.

Ha KC, Lalonde E, Li L, Cavallone L, Natrajan R, Lambros MB, Mitsopoulos C, Hakas J, Kozarewa I, Fenwick K, Lord CJ, Ashworth A, Vincent-Salomon A, Basik M, Reis-Filho JS, Majewski J, Foulkes WD.

BMC Med Genomics. 2011 Oct 27;4:75. doi: 10.1186/1755-8794-4-75.

26.

Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Duprez R, Wilkerson PM, Lacroix-Triki M, Lambros MB, MacKay A, A'Hern R, Gauthier A, Pawar V, Colombo PE, Daley F, Natrajan R, Ward E, MacGrogan G, Arbion F, Michenet P, Weigelt B, Vincent-Salomon A, Reis-Filho JS.

J Pathol. 2012 Feb;226(3):427-441. doi: 10.1002/path.3032. Epub 2011 Dec 9.

27.

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.

Wetterskog D, Lopez-Garcia MA, Lambros MB, A'Hern R, Geyer FC, Milanezi F, Cabral MC, Natrajan R, Gauthier A, Shiu KK, Orr N, Shousha S, Gatalica Z, Mackay A, Palacios J, Reis-Filho JS, Weigelt B.

J Pathol. 2012 Jan;226(1):84-96. doi: 10.1002/path.2974. Epub 2011 Oct 20.

PMID:
22015727
28.

Functional viability profiles of breast cancer.

Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A.

Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2.

29.

Non-existence of caveolin-1 gene mutations in human breast cancer.

Patani N, Lambros MB, Natrajan R, Dedes KJ, Geyer FC, Ward E, Martin LA, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2012 Jan;131(1):307-10. doi: 10.1007/s10549-011-1761-2. Epub 2011 Sep 11.

PMID:
21909981
30.

High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform.

Lambros MB, Wilkerson PM, Natrajan R, Patani N, Pawar V, Vatcheva R, Mansour M, Laschet M, Oelze B, Orr N, Muller S, Reis-Filho JS.

Lab Invest. 2011 Oct;91(10):1491-501. doi: 10.1038/labinvest.2011.110. Epub 2011 Aug 1.

31.

Functional characterization of EMSY gene amplification in human cancers.

Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS.

J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7.

PMID:
21735447
32.

Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype.

Patani N, Barbashina V, Lambros MB, Gauthier A, Mansour M, Mackay A, Reis-Filho JS.

J Clin Pathol. 2011 Sep;64(9):822-8. doi: 10.1136/jclinpath-2011-200135. Epub 2011 Jun 14.

PMID:
21676924
33.

Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology.

Geyer FC, de Biase D, Lambros MB, Ragazzi M, Lopez-Garcia MA, Natrajan R, Mackay A, Kurelac I, Gasparre G, Ashworth A, Eusebi V, Reis-Filho JS, Tallini G.

Breast Cancer Res Treat. 2012 Feb;132(1):15-28. doi: 10.1007/s10549-011-1504-4. Epub 2011 Apr 21.

PMID:
21509527
34.

Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.

Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A, Reis-Filho JS.

Clin Cancer Res. 2011 Mar 15;17(6):1521-34. doi: 10.1158/1078-0432.CCR-10-1688.

35.

Absence of microsatellite instability in mucinous carcinomas of the breast.

Lacroix-Triki M, Lambros MB, Geyer FC, Suarez PH, Reis-Filho JS, Weigelt B.

Int J Clin Exp Pathol. 2010 Nov 27;4(1):22-31.

36.

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.

Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS.

Mod Pathol. 2011 Feb;24(2):209-31. doi: 10.1038/modpathol.2010.205. Epub 2010 Nov 12.

37.

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho JS.

Sci Transl Med. 2010 Oct 13;2(53):53ra75. doi: 10.1126/scitranslmed.3001538.

38.

Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast.

Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB, Reis-Filho JS, Ellis IO.

Am J Surg Pathol. 2010 Oct;34(10):1472-9. doi: 10.1097/PAS.0b013e3181f01916.

PMID:
20871222
39.

Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.

Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, Jones RL, Reis-Filho JS.

Eur J Cancer. 2011 Jan;47(1):138-50. doi: 10.1016/j.ejca.2010.08.007. Epub 2010 Sep 9.

PMID:
20832293
40.

Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.

Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A, Reis-Filho JS.

J Pathol. 2010 Nov;222(3):282-98. doi: 10.1002/path.2763.

PMID:
20815046
41.

β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast.

Lacroix-Triki M, Geyer FC, Lambros MB, Savage K, Ellis IO, Lee AH, Reis-Filho JS.

Mod Pathol. 2010 Nov;23(11):1438-48. doi: 10.1038/modpathol.2010.141. Epub 2010 Aug 6.

42.

PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.

Lambros MB, Natrajan R, Geyer FC, Lopez-Garcia MA, Dedes KJ, Savage K, Lacroix-Triki M, Jones RL, Lord CJ, Linardopoulos S, Ashworth A, Reis-Filho JS.

Mod Pathol. 2010 Oct;23(10):1334-45. doi: 10.1038/modpathol.2010.121. Epub 2010 Jun 11.

43.

Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast.

Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, Parry S, Ashworth A, Badve S, Reis-Filho JS.

Mod Pathol. 2010 Jul;23(7):951-60. doi: 10.1038/modpathol.2010.82. Epub 2010 May 7.

44.

Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study.

Dedes KJ, Lopez-Garcia MA, Geyer FC, Lambros MB, Savage K, Vatcheva R, Wilkerson P, Wetterskog D, Lacroix-Triki M, Natrajan R, Reis-Filho JS.

Breast Cancer Res Treat. 2010 Dec;124(3):653-66. doi: 10.1007/s10549-010-0816-0. Epub 2010 Mar 6.

PMID:
20213079
45.

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.

Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, Ashworth A, van de Vijver MJ, Reis-Filho JS.

Oncogene. 2010 Apr 8;29(14):2013-23. doi: 10.1038/onc.2009.489. Epub 2010 Jan 18.

46.

Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas.

Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, Savage K, Mackay A, Ashworth A, Reis-Filho JS.

J Pathol. 2010 Apr;220(5):562-73. doi: 10.1002/path.2675.

PMID:
20099298
47.

Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma.

Geyer FC, Kushner YB, Lambros MB, Natrajan R, Mackay A, Tamber N, Fenwick K, Purnell D, Ashworth A, Walker RA, Reis-Filho JS.

Histopathology. 2009 Dec;55(6):732-43. doi: 10.1111/j.1365-2559.2009.03432.x.

PMID:
19922592
48.

Genetic characterization of breast cancer and implications for clinical management.

Geyer FC, Lopez-Garcia MA, Lambros MB, Reis-Filho JS.

J Cell Mol Med. 2009 Oct;13(10):4090-103. doi: 10.1111/j.1582-4934.2009.00906.x. Epub 2009 Sep 14. Review.

49.

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.

Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, Pardal F, Amorim J, Mackay A, Milanezi F, Tamber N, Fenwick K, Ashworth A, Reis-Filho JS, Lopes JM, Reis RM.

Br J Cancer. 2009 Sep 15;101(6):973-82. doi: 10.1038/sj.bjc.6605225. Epub 2009 Aug 25.

50.

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.

Marchiò C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A.

J Pathol. 2009 Sep;219(1):16-24. doi: 10.1002/path.2574.

PMID:
19670217

Supplemental Content

Loading ...
Support Center